0001144204-15-000194.txt : 20150102
0001144204-15-000194.hdr.sgml : 20150102
20150102182920
ACCESSION NUMBER: 0001144204-15-000194
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141230
FILED AS OF DATE: 20150102
DATE AS OF CHANGE: 20150102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TG THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001001316
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 363898269
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 787 SEVENTH AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10019
BUSINESS PHONE: (212) 554-4484
MAIL ADDRESS:
STREET 1: 787 SEVENTH AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10019
FORMER COMPANY:
FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030310
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC
DATE OF NAME CHANGE: 20000330
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19960703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WEISS MICHAEL S
CENTRAL INDEX KEY: 0001038977
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32639
FILM NUMBER: 15502229
MAIL ADDRESS:
STREET 1: 750 LEXINGTON AVE
CITY: NEW YORK
STATE: NY
ZIP: 10022
4
1
v397948_4.xml
OWNERSHIP DOCUMENT
X0306
4
2014-12-30
0
0001001316
TG THERAPEUTICS, INC.
TGTX
0001038977
WEISS MICHAEL S
3 COLUMBUS AVE, 15TH FLOOR
NEW YORK
NY
10019
1
1
1
0
See Remarks
COMMON STOCK
2014-12-30
4
A
0
268603
0
A
8389376
D
Reflects a grant of restricted shares that will vest according to the following schedule: 25% on January 1, 2018; 25% on January 1, 2019; and 50% on the later to occur of: (a) the date that the Company's Market Capializaion is $100 million greater than the Market Capitalization on the date of the grant and (b) the 5th anniversary of the date of the grant.
Includes shares of restricted Common Stock, which vest over various time periods. Includes 33,334 warrants to purchase Common Stock at $2.25, exercisable through December 31, 2016. Finally, also included in Mr. Weiss' beneficial ownership are 4,524,560 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest.
Executive Chairman, Interim CEO and President
/s/ Michael Weiss
2015-01-02